180 related articles for article (PubMed ID: 31835965)
1. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy.
Shah A; Shah R; Kebede N; Mohamed A; Botteman M; Waldeck R; Hussain A
J Med Econ; 2020 Apr; 23(4):330-346. PubMed ID: 31835965
[No Abstract] [Full Text] [Related]
2. Adverse events and costs among non-metastatic castration-resistant prostate cancer patients.
Appukkuttan S; Yao J; Partridge J; Kong SX; Parkin J; Freedland SJ
J Med Econ; 2024; 27(1):145-152. PubMed ID: 38174553
[TBL] [Abstract][Full Text] [Related]
3. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
Hussain A; Jiang S; Varghese D; Appukkuttan S; Kebede N; Gnanasakthy K; Macahilig C; Waldeck R; Corman S
BMC Cancer; 2022 Mar; 22(1):304. PubMed ID: 35317768
[TBL] [Abstract][Full Text] [Related]
4. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
5. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.
Pilon D; Behl AS; Ellis LA; Robitaille MN; Lefebvre P; Dawson NA
Am Health Drug Benefits; 2017 May; 10(3):143-153. PubMed ID: 28626511
[TBL] [Abstract][Full Text] [Related]
7. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
Kabadi SM; Near A; Wada K; Burudpakdee C
Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
[TBL] [Abstract][Full Text] [Related]
9. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
10. Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States.
Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Lefebvre P; Pilon D; George D
J Med Econ; 2024; 27(1):381-391. PubMed ID: 38420699
[TBL] [Abstract][Full Text] [Related]
11. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
Irwin DE; Masaquel A; Johnston S; Barnett B
J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
[TBL] [Abstract][Full Text] [Related]
12. Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.
Bretagne M; Lebrun-Vignes B; Pariente A; Shaffer CM; Malouf GG; Dureau P; Potey C; Funck-Brentano C; Roden DM; Moslehi JJ; Salem JE
Arch Cardiovasc Dis; 2020 Jan; 113(1):9-21. PubMed ID: 31685432
[TBL] [Abstract][Full Text] [Related]
13. Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors.
Simpson KN; Chen SY; Wu AW; Boulanger L; Chambers R; Nedrow K; Tawadrous M; Pashos CL; Haider S
HIV Med; 2014 Sep; 15(8):488-98. PubMed ID: 24641448
[TBL] [Abstract][Full Text] [Related]
14. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
Schultz NM; Flanders SC; Wilson S; Brown BA; Song Y; Yang H; Lechpammer S; Kassabian V
Adv Ther; 2018 Oct; 35(10):1639-1655. PubMed ID: 30191463
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry.
Tan YG; Poon RJ; Pang LJ; Villanueva A; Huang HH; Chen K; Ng TK; Tay KJ; Ho HS; Yuen JS
Urol Oncol; 2020 Aug; 38(8):682.e1-682.e9. PubMed ID: 32475745
[TBL] [Abstract][Full Text] [Related]
16. Incidence of corneal adverse events in patients with multiple myeloma and their clinical and economic impact: A real-world retrospective cohort study.
Wang F; Sansbury L; Ferrante S; Maiese EM; Willson J; Chen CC; Nunna S; Sun K; Kleinman DM
J Med Econ; 2022; 25(1):182-192. PubMed ID: 35023807
[TBL] [Abstract][Full Text] [Related]
17. Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study.
Liu JM; Lin CC; Chen MF; Liu KL; Lin CF; Chen TH; Wu CT
Prostate; 2021 Feb; 81(3):194-201. PubMed ID: 33393676
[TBL] [Abstract][Full Text] [Related]
18. Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients.
Kulkarni AA; Rubin N; Tholkes A; Shah S; Ryan CJ; Lutsey PL; Prizment A; Rao A
ESMO Open; 2021 Oct; 6(5):100261. PubMed ID: 34509804
[TBL] [Abstract][Full Text] [Related]
19. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
Borghaei H; Yim YM; Guerin A; Pivneva I; Shi S; Gandhi M; Ionescu-Ittu R
Lung Cancer; 2018 May; 119():112-119. PubMed ID: 29656745
[TBL] [Abstract][Full Text] [Related]
20. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC
Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
